Latest news from Mizuho Americas
-
Pfizer ‘a victim of their own success’ amid lagging COVID vaccine sales: Analyst
- News
-
The case for a rebound in industrials
- News
-
Payments space has seen ‘a mountain of growth,’ analyst says
- News
-
Mizuho maintains neutral rating on Mondelez (MDLZ) stock following earnings
- News
-
Mizuho Americas wins eight IFR awards
- News
-
Investing in oncology-focused companies
- News
-
Mizuho's $650 price target on Intuit (INTU) ahead of tax day
- News
-
The December inflation number will probably be 5% year over year, says Mizuho’s Ricchiuto
- News
-
Oncology stocks as high risk, high reward
- News